Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Holding STRO?
Track your performance easily
STRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.01 - $6.13
Previous Close$3.7
Volume957.02K
Average Volume (3M)767.76K
Market Cap
$303.27M
Enterprise Value-$96.20M
Total Cash (Recent Filing)$425.99M
Total Debt (Recent Filing)$26.53M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 07, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding81,963,659
10 Day Avg. Volume673,862
30 Day Avg. Volume767,758
Standard Deviation0.19
R-Squared0.10
Alpha-0.00643
Financial Highlights & Ratios
Price to Book (P/B)2.16
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)9.80
P/FCF Ratio9.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.57
Enterprise Value/Gross Profit-0.63
Enterprise Value/Ebitda2.89
Forecast
1Y Price Target
$10.83Price Target Upside170.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Sutro Biopharma News
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityThe goal will be to move the combo into the platinum-sensitive ovarian cancer setting, where they see the largest commercial opportunity.
EfficacyThe company saw initial signs of efficacy for the combo irrespective of FolR α expression, potentially expanding the addressable patient population.
SafetyThe combination of luvelta and bevacizumab was relatively well tolerated with no new safety signals observed.
Bears Say
Clinical Data44% of patients experienced treatment-related adverse events leading to discontinuation, which is higher compared to 38% for mirv+bev.
Market OutlookShares are likely to remain range bound due to lack of catalysts, with no immediate stock-moving events anticipated.
Share PerformanceShares are down 30% year-to-date, largely due to the lack of clinical catalysts.
---
Ownership Overview
18.13% Insiders
11.67% Mutual Funds
42.48% Other Institutional Investors
27.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $2.00 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Currently, no data Available
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Aug 13, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.792 by $0.202.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -$0.74.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 81,963,660 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.792. Following the earnings report the stock price went up 11.491%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Among the largest hedge funds holding Sutro Biopharma Inc’s share is Fisher Asset Management LLC. It holds Sutro Biopharma Inc’s shares valued at 795K.
---
Sutro Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.83 (170.07% Upside)
$10.83 (170.07% Upside)
Hedge Fund Trend
Decreased
By 11.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.37%
12-Months-Change
Fundamentals
Return on Equity
-81.10%
Trailing 12-Months
Asset Growth
5.19%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.83
▲(170.07% Upside)
Technical Analysis
Best Analysts Covering STRO
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+0.94%
reiterated a buy rating last month
Copying David Nierengarten's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +0.94% per trade.
---